| FORM | 4 |
|------|---|
|------|---|

(Print or Type Responses)

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person-<br>RODRIGUEZ RAUL R | 2. Issuer Name and<br>RIGEL PHARMA         |  |  |          | RIGL]   | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>X Director 10% Owner |  |   |  |                         |  |
|--|--|--|--|----------|---|--|--|---|--|-------------------------|--|
| (First)<br>RIGEL PHARMACEUTICALS, IN<br>VETERANS BLVD.       | 10. 1100                                   | 3. Date of Earliest Transaction (Month/Day/Year)<br>03/20/2019 |  |          |   |  |  | X_Officer (give title below)Other (specify below) _ |  |                         |  |
| (Street)<br>SOUTH SAN FRANCISCO, CA 9                        |  | 4. If Amendment, Date Original Filed(Month/Day/Year)           |  |          |   |  |  | 6. Individual or Joint/Group Filing(Check Applicable Line)<br>_X_Form filed by One Reporting Person<br>Form filed by More than One Reporting Person   |  |                         |  |
| (City) (State)   | (Zip)                                      | Table I - Non-Derivative Securities Acqu                       |  |          |   |  | ired, Disposed of, or Beneficially Owned |   |  |                         |  |
| 1.Title of Security<br>(Instr. 3)                            | 2. Transaction<br>Date<br>(Month/Day/Year) | Execution Date, if   | 3. Transacti<br>Code<br>(Instr. 8)<br>Code | ion<br>V | (A) or Disposed of (D)<br>(Instr. 3, 4 and 5) |  | of (D)                                   | 5. Amount of Securities Beneficially<br>Owned Following Reported<br>Transaction(s)<br>(Instr. 3 and 4)  | 6.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) | Beneficial<br>Ownership |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

| _   | (e.g., puts, calls, warrants, options, convertible securities)        |                          |   |      |           |  |            |  |                    |  |                                     |                                      |  |   |                                       |
|---|---|--------------------------|---|------|-----------|--|------------|--|--------------------|--|-------------------------------------|--------------------------------------|--|---|---------------------------------------|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | Code | tion<br>) | 5. Number<br>Derivative<br>Securities<br>Acquired (<br>or Dispose<br>(D)<br>(Instr. 3, 4<br>and 5) | A)<br>d of | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>of Underlying<br>Securities |                                     | Derivative<br>Security<br>(Instr. 5) | Derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s) | Derivative<br>Security:<br>Direct (D)<br>or Indirect<br>(I) | Beneficial<br>Ownership<br>(Instr. 4) |
|   |   |                          |   | Code | v         | (A)  | (D)        | Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares |                                      | (Instr. 4)   | (Instr. 4)  |                                       |
| Employee<br>Stock<br>Option<br>(right to<br>buy)    | \$ 4.49   | 03/20/2019               |   | А    |           | 237,500  |            | (1)  | 01/24/2028         | Common<br>Stock                                    | 237,500                             | \$ 0                                 | 237,500  | D   |                                       |

## **Reporting Owners**

|   | Relationships |              |                |       |  |  |  |
|---|---------------|--------------|----------------|-------|--|--|--|
| Reporting Owner Name / Address  | Director      | 10%<br>Owner | Officer        | Other |  |  |  |
| RODRIGUEZ RAUL R<br>RIGEL PHARMACEUTICALS, INC.<br>1180 VETERANS BLVD.<br>SOUTH SAN FRANCISCO, CA 94080 | Х             |              | CEO, President |       |  |  |  |

### Signatures

| /s/ Dolly Vance (Attorney-in-Fact) | 03/22/2019 |
|------------------------------------|------------|
| Signature of Reporting Person      | Date       |

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On January 24, 2018, the reporting person was granted a performance based option to purchase 237,500 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.